October 2016 VOL 7, NO 9

← Back to Issue

Category I: Patient Education, Seventh Annual AONN+ Conference Abstracts

3. How Patient and Caregiver Informational and Psychosocial Needs Are Being Met in Practice: Results from a National Melanoma Survey

Claire Saxton, MBA; Marni Amsellem, PhD; Rhea Suarez
Cancer Support Community, Washington, DC 

Objectives: Cancer patients and caregivers often have significant psychosocial and informational needs. Many healthcare providers and navigators make referrals to educational and support resources, but how well are the concerns of those affected actually being met? The Cancer Support Community (CSC) and its partners asked that question to those affected by melanoma to better understand this population’s unique needs, to inform a survivorship program for those at high risk for melanoma recurrence, and to inform CSC’s Frankly Speaking About Melanoma educational program.

Methods: In the spring of 2016, CSC along with a team of experts developed a survey of those affected by melanoma; 140 individuals diagnosed with melanoma and 64 melanoma caregivers participated in a national online survey reporting melanoma-related beliefs, information-seeking, provision of information, informational preferences, behaviors, and other melanoma-related experiences.

Results: Patients were Caucasian (95%), female (87.9%), and averaged 49.2 years of age (SD = 10.5). Nearly half (48.1%) were diagnosed with metastatic melanoma; 47.6% had recurrent melanoma. Respondents reported distress, with most experiencing anxiety (60%) or depression (53.6%). Whereas most (69%) received information about treatment choices, only 39.5% received resources for social and emotional support. Half (52.7%) were asked by their healthcare team about cancer-related distress; 42.0% were provided with referrals from their healthcare team to help manage distress. Only 8.9% received a survivorship care plan. Most wished they had received more help understanding recurrence risk (70%), managing fear of recurrence (68%), and cancer-related emotions (64.3%).

Caregivers were Caucasian (90.4%), female (90.1%), and averaged 47.1 years of age (SD = 14.8). Caregivers sought information about melanoma from patients’ doctors (43.8%), nurses (26.6%), the Internet (54.7%), patient support organizations (25.0%), and hospital resource rooms (21.9%). Many (53.8%) reported they would benefit from getting support for themselves, managing stress (46.2%), or taking better care of themselves (44.2%). Only 12.2% received referrals to help manage distress.

Conclusions: Results explore the depth and breadth of information and support needs of those affected by melanoma. Results suggest that while many diagnostic and treatment-related informational needs are met, psychosocial needs are not as well met, leaving both patients and caregivers desiring more. Findings highlight what it would mean to provide comprehensive and relevant information and support resources for this population, particularly resources for understanding risk and managing fear of recurrence and distress-related referrals.

Disclosures: This research was made possible by unrestricted educational grants from Bristol-Myers Squibb and Merck.

Related Articles
Category VII: Clinical Research, Seventh Annual AONN+ Conference Abstracts - September 23, 2016

43. A Novel Approach for 2-Stage Breast Reconstruction: Patient-Controlled Tissue Expansion Using the AeroForm CO2 Tissue Expander System

Objectives: The tissue expansion process using standard of care, saline-filled expanders is lengthy, inconvenient, and uncomfortable and may lead women to make the decision to decline breast reconstruction. The efficacy [ Read More ]

Category VII: Clinical Research, Seventh Annual AONN+ Conference Abstracts - September 23, 2016

48. Restoring Quality of Life and Hematologic Function with Ibrutinib in Treatment-Naive Patients with Chronic Lymphocytic Leukemia in the RESONATE-2 Study

Objectives: Disease symptoms and treatment complications can profoundly affect quality of life (QOL) in patients (pts) with chronic lymphocytic leukemia (CLL). Ibrutinib (ibr), a B-cell receptor pathway inhibitor, improved QOL [ Read More ]